AE Wealth Management LLC Purchases 7,645 Shares of Gilead Sciences, Inc. $GILD

AE Wealth Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,319 shares of the biopharmaceutical company’s stock after purchasing an additional 7,645 shares during the quarter. AE Wealth Management LLC’s holdings in Gilead Sciences were worth $3,916,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Penserra Capital Management LLC grew its stake in Gilead Sciences by 1,241.2% in the 2nd quarter. Penserra Capital Management LLC now owns 1,368 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 1,266 shares in the last quarter. KCM Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 15.2% in the second quarter. KCM Investment Advisors LLC now owns 11,060 shares of the biopharmaceutical company’s stock valued at $1,226,000 after purchasing an additional 1,460 shares during the period. Wedbush Securities Inc. grew its position in shares of Gilead Sciences by 1.3% during the 2nd quarter. Wedbush Securities Inc. now owns 18,187 shares of the biopharmaceutical company’s stock worth $2,016,000 after buying an additional 238 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in Gilead Sciences during the 2nd quarter valued at about $214,000. Finally, Aspect Partners LLC raised its holdings in shares of Gilead Sciences by 94.0% in the 2nd quarter. Aspect Partners LLC now owns 322 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 156 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.6%

NASDAQ GILD opened at $118.15 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm’s 50-day moving average is $116.59 and its two-hundred day moving average is $112.34. The stock has a market capitalization of $146.60 billion, a P/E ratio of 23.54, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 71,500 shares of company stock worth $8,336,040. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, BMO Capital Markets raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $128.27.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.